Since April 2022, Ian Muir has served as Chief Executive Officer of Pharmaxo Group – the parent company of Bath ASU, Pharmaxo Healthcare, and Pharmaxo Scientific – steering the organisation through a period of rapid expansion and strategic realignment.
Under his leadership, the Group re-branded, and was acquired by Icon Group in 2024, enabling new capability to deliver high-quality aseptic compounding and clinical homecare services across the UK.
Ian is responsible for shaping Pharmaxo’s growth strategy, strengthening operational performance across its manufacturing and home-infusion network, and embedding a culture of quality and patient-centred care.
A pharmaceutical scientist by training, Ian holds a PhD in pharmaceutical science and brings more than three decades of international experience. He has held senior commercial, R&D and manufacturing roles with Catalent globally and Aesica, Famar and Porton Biopharm as CEO. He was a member of the UK, Vaccine Task Force for vaccine manufacture as well as advising financial and industry investors on M&A in the sector.
This breadth of leadership gives him a deep understanding of the end-to-end pharmaceutical value chain.
His vision is clear; to extend world-class, specialist medicines and homecare services to every patient who needs them, while building a resilient, responsible organisation that delivers lasting value for partners, caregivers and the communities it serves.